Caris Life Sciences IPO

carislifesciences.comHealthcare / BioTech & Pharma

Caris Life Sciences was founded in 1996 by David Halbert. After raising $130 million in fresh capital in 2021, CFO Thomas Parker told reporters that the company is considering an IPO. "The size of the company’s scale, our future pipeline — some of those things — are pretty well suited for the public markets," he said. "We're taking a serious look at that this year. That doesn’t mean we have definite plans."

Caris Life Sciences is a medical technology company that specializes in molecular profiling, using AI to guide personalized cancer treatments. In 2021, the company announced an $830 million growth equity round, bringing its total funding to $1.3 billion. Investors include Sixth Street Partners, Canada Pension Plan Investment Board, ClearBridge Investments, and Coatue Management. Caris announced a post-money valuation of $7.83 billion.

These comments should not be interpreted to mean that the company is formally pursuing or foregoing an IPO.

Buy or sell Caris Life Sciences stock Learn more about Caris Life Sciences stock

Learn more about Caris Life Sciences

Is Caris Life Sciences a publicly traded company?

Caris Life Sciences is a private company and not publicly traded.

If you are interested in buying or selling private company shares, you can register with Forge today for free to explore your options. Registering gives you access to one of our Private Market Specialists who can guide you through the process of buying or selling. Learn more about how Forge might help you buy pre-IPO shares or sell pre-IPO shares.

Will Caris Life Sciences go IPO?

Caris Life Sciences has not yet filed for an IPO. However, it's important to note that IPOs are not the sole avenue for a private company to transition to public trading. Private companies can also go public through alternative methods such as but limited to Special Purpose Acquisition Companies (SPACs), direct listings, or through mergers and acquisitions. Find out which companies are eyeing an IPO on our Tech IPO Calendar 2024.

What is Caris Life Sciences's IPO price?

The IPO price for Caris Life Sciences will be known only if it becomes public. However, you may access the "Price At Last Round" and the "Implied EV" for publicly traded comparable companies with Forge Data.

Can you invest in Caris Life Sciences pre-IPO?

Caris Life Sciences is privately held company and is not publicly traded, therefor investing in Caris Life Sciences pre-IPO is only available to accredited investors. If you meet the accreditation criteria, you can register for Forge’s Secondary Marketplace to invest in private companies before their potential IPO. If you are not an accredited investor, discover how to begin the the process to potentially qualify for new investment opportunities.

What is the value of my Caris Life Sciences shares?

To determine the value of your Caris Life Sciences shares, create a free account to gain access to Forge’s platform. Forge Markets contains pricing information for hundreds of pre-IPO companies. A Private Market Specialist will also be available to assist you with any inquiries related to your Caris Life Sciences shares. You can also learn more about how to sell your private shares before getting started.

Can you sell Caris Life Sciences before it goes public?

Yes, you can seek to sell shares in Caris Life Sciences while it remains private. If you are considering selling, you can register today for free to get started. Once registered, a Private Market Specialist will guide you through any questions you might have. You may also continue to browse through our resources to help you understand the implications and procedures involved in selling your private market shares.

What is Caris Life Sciences's funding to date?

Caris Life Sciences has raised $465MM to date.

When was Caris Life Sciences founded?

Caris Life Sciences was founded in 2008.

Who are Caris Life Sciences's major investors?

Coatue Management

Fidelity Management & Research

T. Rowe Price

ClearBridge

Neuberger Berman

Silver Lake

Rock Springs Capital

Sixth Street Partners

Millennium Management

OrbiMed

J.H. Whitney Capital Partners

Frequently Asked Questions

Updated on: Jul 26, 2024

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.